AR010873A1 - Compuestos antagonistas del receptor de vitronectina, intermediarios, metodos de su preparacion, composiciones farmaceuticas, uso de dichoscompuestos para la fabricacion de medicamentos. - Google Patents

Compuestos antagonistas del receptor de vitronectina, intermediarios, metodos de su preparacion, composiciones farmaceuticas, uso de dichoscompuestos para la fabricacion de medicamentos.

Info

Publication number
AR010873A1
AR010873A1 ARP980100031A ARP980100031A AR010873A1 AR 010873 A1 AR010873 A1 AR 010873A1 AR P980100031 A ARP980100031 A AR P980100031A AR P980100031 A ARP980100031 A AR P980100031A AR 010873 A1 AR010873 A1 AR 010873A1
Authority
AR
Argentina
Prior art keywords
compounds
intermediaries
manufacture
preparation
methods
Prior art date
Application number
ARP980100031A
Other languages
English (en)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR010873A1 publication Critical patent/AR010873A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se refiere a compuestos antagonistas receptores de vitronectina de las estructuras (I), que son utiles para el tratamiento de inflamacion, cáncer ydesordenes cardiovasculares, tales como arteriosclerosis y restenosis, y enfermedades endo nde la resorcion osea es un factor, tal como osteoporosis.También se relaciona con intermediarios, métodos de su preparacion, uso de dichos compuestos para la fabricacion de un medicamento.
ARP980100031A 1997-01-08 1998-01-05 Compuestos antagonistas del receptor de vitronectina, intermediarios, metodos de su preparacion, composiciones farmaceuticas, uso de dichoscompuestos para la fabricacion de medicamentos. AR010873A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3402697P 1997-01-08 1997-01-08

Publications (1)

Publication Number Publication Date
AR010873A1 true AR010873A1 (es) 2000-07-12

Family

ID=21873846

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980100031A AR010873A1 (es) 1997-01-08 1998-01-05 Compuestos antagonistas del receptor de vitronectina, intermediarios, metodos de su preparacion, composiciones farmaceuticas, uso de dichoscompuestos para la fabricacion de medicamentos.

Country Status (30)

Country Link
US (2) US6069158A (es)
EP (1) EP0977735B1 (es)
JP (1) JP2001508067A (es)
KR (1) KR20000069941A (es)
CN (1) CN1249745A (es)
AP (1) AP9901597A0 (es)
AR (1) AR010873A1 (es)
AT (1) ATE235467T1 (es)
AU (1) AU729641B2 (es)
BG (1) BG103548A (es)
BR (1) BR9806852A (es)
CA (1) CA2276738A1 (es)
CO (1) CO4920232A1 (es)
DE (1) DE69812602T2 (es)
DZ (1) DZ2395A1 (es)
EA (1) EA199900630A1 (es)
ES (1) ES2196534T3 (es)
HU (1) HUP0001945A3 (es)
ID (1) ID23168A (es)
IL (1) IL130760A0 (es)
MA (1) MA26462A1 (es)
NO (1) NO993350L (es)
NZ (1) NZ336560A (es)
OA (1) OA11076A (es)
PE (1) PE44799A1 (es)
PL (1) PL334499A1 (es)
SK (1) SK92799A3 (es)
TR (1) TR199901575T2 (es)
WO (1) WO1998030542A1 (es)
ZA (1) ZA9896B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011626A1 (en) * 1997-09-04 1999-03-11 Smithkline Beecham Corporation Integrin receptor antagonists
US6576643B2 (en) 1997-09-19 2003-06-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
DZ2609A1 (fr) * 1997-09-19 2003-03-01 Smithkline Beecham Corp Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant.
ATE542797T1 (de) 1998-04-09 2012-02-15 Meiji Seika Pharma Co Ltd Aminopiperidinderivate als integrin alpha v beta 3 antagonisten
JP4240424B2 (ja) * 1998-10-23 2009-03-18 エルジー ディスプレイ カンパニー リミテッド エッチング剤及びこれを用いた電子機器用基板の製造方法
US6339083B1 (en) 1998-12-14 2002-01-15 Bayer Aktiengesellschaft Multiheterocyclic pharmAceuticals
AU747503B2 (en) 1999-02-03 2002-05-16 Merck & Co., Inc. Benzazepine derivatives as alpha-V integrin receptor antagonists
DE19916837A1 (de) * 1999-04-14 2000-10-19 Merck Patent Gmbh Dibenzoazulenderivate
US6750219B1 (en) 1999-08-05 2004-06-15 Meiji Seika Kaisha, Ltd. Ω-amino-α-hydroxycarboxylic acid derivatives having integrin ανβ3 antagonistic activity
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
FR2806082B1 (fr) * 2000-03-07 2002-05-17 Adir Nouveaux composes bicycliques antagonistes des recepteurs de la vitronectine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6943156B2 (en) 2000-10-24 2005-09-13 Merck & Co., Inc Dibenzoxazepine αv integrin receptor antagonist
WO2002085405A2 (en) 2001-04-24 2002-10-31 Merck Patent Gmbh COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
CA2464472C (en) 2001-10-22 2014-01-07 The Scripps Research Institute Antibody targeting compounds
GB0215867D0 (en) * 2002-07-09 2002-08-14 Glaxosmithkline Spa Novel method and compounds
AU2012216372B2 (en) * 2004-04-02 2015-01-22 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
AU2005229015C1 (en) * 2004-04-02 2013-01-17 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with alphaVbeta5 integrin
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006128689A2 (de) 2005-05-31 2006-12-07 Ralf Jochem Therapeutsche zusammensetzung zur vorbeugung und bekämpfung von knochenmetastasen
US20070122408A1 (en) * 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
JP2009523813A (ja) 2006-01-18 2009-06-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法
PL2101805T3 (pl) 2007-01-18 2013-04-30 Merck Patent Gmbh Ligandy integryn do stosowania w leczeniu nowotworów
PT2222636E (pt) 2007-12-21 2013-07-16 Ligand Pharm Inc Moduladores seletivos de recetores de andrógeno (sarms) e suas utilizações
US8518927B2 (en) 2009-02-10 2013-08-27 The Scripps Research Institute Chemically programmed vaccination
KR20120104491A (ko) 2009-05-25 2012-09-21 메르크 파텐트 게엠베하 암 치료를 위한 실렌기티드의 연속 투여
WO2011011775A1 (en) 2009-07-24 2011-01-27 The Regents Of The University Of California Methods and compositions for treating and preventing disease associated with avb5 integrin
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794424A (fr) * 1972-01-24 1973-07-23 Science Union & Cie Nouveaux dibenzocycloheptenes, leur procede d'obtention et leur application comme medicament
US3906032A (en) * 1972-11-10 1975-09-16 Squibb & Sons Inc Dihydroxy-tetrahydronaphthyoxyisobutyric acids and alkyl esters and salts thereof
IT1222986B (it) * 1987-10-23 1990-09-12 Texcontor Ets Derivati dell'efedrina esterificata aventi attivita' antiulcera prolungata nel tempo
US4994463A (en) * 1987-12-14 1991-02-19 Kyowa Hakko Kogyo Co., Ltd. Tricyclic thromboxane A2 antagonists
EP0910563B1 (en) * 1995-06-29 2003-05-02 Smithkline Beecham Corporation Integrin receptor antagonists
WO1997024124A1 (en) * 1995-12-29 1997-07-10 Smithkline Beecham Corporation Vitronectin receptor antagonists
EP1000031A4 (en) * 1997-07-25 2001-08-16 Smithkline Beecham Corp VITRONECTIN RECEPTOR ANTAGONISTS
DZ2609A1 (fr) * 1997-09-19 2003-03-01 Smithkline Beecham Corp Composés nouveaux antagonistes des récepteurs de vitronectine et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
IL130760A0 (en) 2001-01-28
AU729641B2 (en) 2001-02-08
EP0977735A4 (en) 2000-04-05
US6191304B1 (en) 2001-02-20
KR20000069941A (ko) 2000-11-25
EP0977735A1 (en) 2000-02-09
ID23168A (id) 2000-03-23
BR9806852A (pt) 2001-08-07
WO1998030542A1 (en) 1998-07-16
NO993350D0 (no) 1999-07-07
EA199900630A1 (ru) 2000-02-28
CO4920232A1 (es) 2000-05-29
CN1249745A (zh) 2000-04-05
JP2001508067A (ja) 2001-06-19
ZA9896B (en) 1998-10-14
ES2196534T3 (es) 2003-12-16
NO993350L (no) 1999-09-06
CA2276738A1 (en) 1998-07-16
DE69812602D1 (de) 2003-04-30
ATE235467T1 (de) 2003-04-15
US6069158A (en) 2000-05-30
HUP0001945A3 (en) 2001-12-28
AU5912798A (en) 1998-08-03
NZ336560A (en) 2000-11-24
PL334499A1 (en) 2000-02-28
TR199901575T2 (xx) 1999-11-22
EP0977735B1 (en) 2003-03-26
SK92799A3 (en) 1999-12-10
DZ2395A1 (fr) 2003-06-04
HUP0001945A2 (hu) 2000-10-28
BG103548A (en) 2000-11-30
DE69812602T2 (de) 2004-02-19
AP9901597A0 (en) 1999-09-30
OA11076A (en) 2003-03-13
PE44799A1 (es) 1999-06-10
MA26462A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
AR010873A1 (es) Compuestos antagonistas del receptor de vitronectina, intermediarios, metodos de su preparacion, composiciones farmaceuticas, uso de dichoscompuestos para la fabricacion de medicamentos.
ES2134859T3 (es) Derivados de 4-carboxoamido-piperidina, productos intermedios y uso como antagonistas de neurokinina.
ECSP055681A (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
UY25421A1 (es) Antagonistas de receptor de vitronectina
SV2004000061A (es) Moduladores del receptor glucocorticoide ref. 10118 amag/bb
UY27199A1 (es) Nuevos compuestos antiinflamatorios de triazolopiridinas
PA8510201A1 (es) Compuestos de amida y composiciones farmacèuticas para inhibir proteinquinasas, y su modo de empleo
PA8446001A1 (es) Derivados de n-hidroxi-b-sulfonilpropionamida
CO5180642A1 (es) Compuestos sustituidos de piperidina, procesos para su prepa racion, composiciones farmaceuticas que los contienen y su utilizacion
ATE306477T1 (de) Selektive npy (y5) antagonisten
ES2168487T3 (es) Derivados de n-heteroaril-piridinasulfonamida y su uso como antagonistas de la endotelina.
UY28945A1 (es) Derivados de pirrolopiridina
PA8509901A1 (es) Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular.
ES2072323T3 (es) Compuestos de piperidina y su preparacion y empleo.
AR005987A1 (es) Terapia combinada para la osteoporosis
BR9808010B1 (pt) Compostos de 2-alquil-19-nor-vitamina d e composição farmacêutica compreendendo os mesmos
PA8583301A1 (es) Nuevos compuestos de imidazol como inhibidores del factor de crecimiento transformante (tgf)
AR029463A1 (es) Pirrolidinas disustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento
DK1305030T3 (da) Anvendelse af 2-alfa-methyl-19-nor-20(S)-1-alfa,25-dihydroxyvitamin-D3 til knogleerstatning
AR002268A1 (es) Antagonistas de vasopresina de benzacepina triciclicos, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso dedichos compuestos para preparar composiciones farmaceuticas.
CA2416194A1 (en) Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 to increase bone strength
BRPI0107493B8 (pt) substâncias para uso no tratamento de psoríase
AR004480A1 (es) Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
PT912185E (pt) Novas formulacoes farmaceuticas contendo derivados de ester nitrato de esteroides proveitosos como farmacos anti-inflamatorios
UY26877A1 (es) Compuestos pirazol-tiazol, composiciones farmacéuticas que los contienen, y su modo de empleo para inhibir quinasas ciclino- dependientes

Legal Events

Date Code Title Description
FA Abandonment or withdrawal